

## ASX ANNOUNCEMENT – Results of Special Meeting of Stockholders

**Minnesota, United States and Melbourne, Australia – 30 August 2016** – Osprey Medical Inc. (ASX: OSP) held a Special Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Special Meeting and Proxy Statement dated 18 August 2016 were passed.

The information required under Section 251AA of the Corporations Act is attached.

Brendan Case  
Australian Secretary

### About Osprey

Osprey Medical, Inc. is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr. David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

### Contact details:

#### Media

Gavin Lower  
Buchan Consulting  
T: (613) 8866 1215  
[glower@buchanwe.com.au](mailto:glower@buchanwe.com.au)

#### Investors

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

#### Company

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)



SPECIAL MEETING - COMMON STOCK  
Tuesday, 30 August, 2016

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

| Resolution  | Manner in which the securityholder directed the proxy vote<br>(as at proxy close): |                         |                               |                         | Manner in which votes were cast in person or by<br>proxy on a poll (where applicable) |                           |                           |
|---|--|-------------------------|-------------------------------|-------------------------|---|---------------------------|---------------------------|
|   | Votes<br><i>For</i>  | Votes<br><i>Against</i> | Votes<br><i>Discretionary</i> | Votes<br><i>Abstain</i> | <i>For</i>  | <i>Against</i>            | <i>Abstain **</i>         |
| 1 RATIFICATION AND APPROVAL OF ISSUE OF CDIS UNDER TRANCHE 1 OF PLACEMENT | 38,967,728   | 0                       | 4,129                         | 187,696                 | Passed on a show of hands   | Passed on a show of hands | Passed on a show of hands |
| 2 APPROVAL FOR ISSUE OF CDIS UNDER TRANCHE 2 OF PLACEMENT                 | 33,593,538   | 58,150                  | 4,129                         | 181,046                 | Passed on a show of hands   | Passed on a show of hands | Passed on a show of hands |
| 3 APPROVAL OF NEW 2016 STOCK INCENTIVE PLAN                               | 47,342,220   | 242,249                 | 129                           | 10,000                  | Passed on a show of hands   | Passed on a show of hands | Passed on a show of hands |

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item